Antibacterial mask

Abstract

The invention provides an antibacterial mask, and relates to the technical field of masks. The antibacterial mask comprises a protective layer, a filter layer and a skin-friendly layer which are sequentially arranged from outside to inside; the protective layer is used for blocking large-particle impurities in the external environment; the filter layer is used for filtering one or more harmful substances in the external environment; the skin-friendly layer is used for being in direct contact with the face skin of a wearer; the medicine release device is connected with the protective layer, the medicine release device is provided with at least one medicine release end, the medicine release end penetrates through the protective layer and is arranged between the protective layer and the filter layer, and the medicine release device is used for releasing medicine between the protective layer and the filter layer. According to the technical scheme, new antibacterial drugs can be continuously supplemented to the area between the protective layer and the filter layer, a good antibacterial environment is maintained, the antibacterial effective duration of the mask is effectively prolonged, and the replacement frequency of the mask is reduced.

Description

Technical Field

[0001] The present disclosure relates to the technical field of face masks, and in particular to an antibacterial face mask. Background Art

[0002] As people pay more and more attention to health and environmental hygiene, the demand for protective equipment is increasing, especially in airports, ports, land border inspection stations, other passenger inspection ports and laboratories.

[0003] During epidemics, port workers face a high risk of disease transmission, necessitating effective protective measures to safeguard their health. They typically use medical isolation masks, which completely cover the face from forehead to chin, providing excellent protection. Among these, masks utilize nanotechnology-processed materials, such as those coated with nano-silver ions. Silver ions possess potent antimicrobial properties, effectively inhibiting the growth and reproduction of bacteria, fungi, and other microorganisms, maintaining a relatively good antimicrobial effect.

[0004] However, although this mask has a certain antibacterial effect, given the high traffic volume at passenger inspection ports and the large number of bacteria and other microorganisms in the environment, this nano-silver ion coated mask needs to be replaced relatively frequently to ensure good antibacterial effect. However, it has its own high cost problem, and frequent replacement will inevitably greatly increase the cost of material procurement at the passenger inspection port. Moreover, during the peak period of an epidemic, if there is a shortage of protective materials, the staff at the passenger inspection port may not be able to obtain enough new masks in time for replacement. This will inevitably affect the effective level of protection they receive, and thus significantly increase the risk of contracting the disease.

[0005] Therefore, an antibacterial mask is needed to at least solve the above problems. Summary of the Invention

[0006] The purpose of the embodiments of the present disclosure is to provide an antibacterial mask that can maintain a good antibacterial effect after long-term use and reduce the frequency of replacement.

[0007] To solve the above technical problems, the present disclosure provides the following technical solutions:

[0008] The present disclosure provides an antibacterial mask, comprising: a protective layer, a filter layer, and a skin-friendly layer arranged in sequence from the outside to the inside; the protective layer is used to block large particles of impurities in the external environment; the filter layer is used to filter one or more harmful substances in the external environment; the skin-friendly layer is used to directly contact the wearer's facial skin; a drug release device, the drug release device is connected to the protective layer, the drug release device has at least one drug release end, the drug release end passes through the protective layer and is arranged between the protective layer and the filter layer, and the drug release device is used to release drugs between the protective layer and the filter layer.

[0009] In some embodiments, the drug delivery device comprises:

[0010] A shell, which is fastened to the surface of the protective layer and forms a storage space with the protective layer; a medicine storage tank, which is used to store medicine and is arranged in the storage space and connected to the medicine release end; a driving unit, which is connected to the medicine storage tank and is used to drive the medicine in the medicine storage tank into the medicine release end.

[0011] In some embodiments, the drug release device further includes a connecting tube, which is connected to the drug storage tank and the drug release end respectively; the connecting tube is a hose.

[0012] In some embodiments, the drug releasing end is a plate-like structure, and there are multiple drug releasing ends, and the multiple drug releasing ends are evenly distributed between the protective layer and the filter layer; there is a distance between the protective layer and the filter layer, and the distance is adapted to the thickness of the drug releasing end.

[0013] In some embodiments, the drug release device further includes a detection unit and a control unit. The detection unit is disposed between the protective layer and the filter layer, and the detection unit is used to detect the concentration of viruses or bacteria between the protective layer and the filter layer; the control unit is respectively communicated with the detection unit and the drive unit, and the control unit controls the start and stop of the drive unit according to the detection results of the detection unit.

[0014] In some embodiments, the filter layer includes a first antibacterial layer, a second antibacterial layer, and a third antibacterial layer that are stacked; the first antibacterial layer is arranged close to the protective layer, and the first antibacterial layer is made of an antibacterial material containing copper ions; the second antibacterial layer is located between the first antibacterial layer and the third antibacterial layer, and the second antibacterial layer is made of a material containing nanosilver; the third antibacterial layer is arranged close to the skin-friendly layer, and the third antibacterial layer is made of a material containing natural plant antibacterial extracts.

[0015] In some embodiments, the antibacterial mask further comprises: an isolation layer, wherein the isolation layer is disposed between the filter layer and the skin-friendly layer, and the isolation layer is used to prevent the drug from contacting the skin-friendly layer.

[0016] In some embodiments, the antibacterial mask further includes: a plurality of connecting parts, each of which is rod-shaped and made of fiber material, and the two ends of the connecting part are respectively connected to the protective layer and the filter layer; the plurality of connecting parts are evenly distributed between the protective layer and the filter layer, and the connecting parts are arranged to avoid the range where the drug release end is located.

[0017] In some embodiments, a plurality of the connecting portions are located on the surface of the filter layer to form a pair of oppositely arranged accommodating areas, and the pair of the accommodating areas are respectively arranged corresponding to the cheek sides of the wearer, and each of the accommodating areas is used to place a drug releasing end, and the size of the accommodating area is adapted to the drug releasing end; the drug releasing end is respectively contacted with the filter layer and the protective layer on both side surfaces along its thickness direction, and the drug releasing end is provided with a plurality of through holes along the circumferential side surface perpendicular to the thickness direction, and the drug enters between the plurality of the connecting portions through the through holes; the drug is in any one of mist, granular or liquid form.

[0018] In some embodiments, the air permeability of the protective layer is greater than that of the filter layer, the drug is in granular form, and the drug can be vaporized under temperature changes.

[0019] Compared with the existing technology, the antibacterial mask provided by the present invention blocks larger particles from entering the interior of the mask through the protective layer, filters smaller particles and microorganisms through the filter layer, makes the wearer feel comfortable when in contact with the face through the skin-friendly layer, and releases drugs between the protective layer and the filter layer through the drug release device. New antibacterial drugs can be continuously added to the area between the protective layer and the filter layer to maintain a good antibacterial environment, thereby effectively extending the antibacterial effective time of the mask and reducing the frequency of mask replacement. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The above and other objects, features and advantages of the exemplary embodiments of the present disclosure will become readily understood by reading the detailed description below with reference to the accompanying drawings. In the accompanying drawings, several embodiments of the present disclosure are shown in an exemplary and non-limiting manner, and the same or corresponding reference numerals represent the same or corresponding parts, wherein:

[0021] Figure 1 The structure diagram of the antibacterial mask disclosed in the present invention is schematically shown;

[0022] Figure 2 Schematically shows a partial cross-sectional structural diagram of the antibacterial mask disclosed herein;

[0023] Figure 3 Schematically shows a projection view of the connecting portion and the drug-releasing end of the antibacterial mask of the present disclosure on the surface of the filter layer;

[0024] Figure 4 A side view of a protective cover in an antimicrobial face mask of the present disclosure is schematically shown.

[0025] Description of Figure Numbers:

[0026] 1. Protective layer; 2. Filter layer; 3. Skin-friendly layer; 4. Drug-releasing device; 401. Shell; 402. Shell cover; 403. Drug-releasing end; 404. Drug storage tank; 405. Drive unit; 406. Connecting pipe; 407. Detection unit; 408. Control unit; 409. Through hole; 5. Isolation layer; 6. Connecting part; 7. Drug; 8. Protective cover; 801. Breathing hole; 802. Shielding part. DETAILED DESCRIPTION

[0027] Exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. Although exemplary embodiments of the present disclosure are shown in the accompanying drawings, it should be understood that the present disclosure can be implemented in various forms and should not be limited by the embodiments described herein. Rather, these embodiments are provided to enable a more thorough understanding of the present disclosure and to fully convey the scope of the present disclosure to those skilled in the art.

[0028] It should be noted that, unless otherwise specified, the technical or scientific terms used in the present disclosure should have the common meanings understood by those skilled in the art to which the present disclosure belongs.

[0029] During epidemics, workers at border crossings face the heightened risk of disease transmission and urgently need effective protection. They often use full-face medical isolation masks, such as those coated with nano-silver ions, which have strong antimicrobial properties and maintain a high level of effectiveness. However, due to the high volume of personnel and microbial activity at border crossings, these masks require frequent replacement, which is costly and significantly increases procurement costs. Furthermore, if supply becomes insufficient, workers will struggle to obtain sufficient replacement masks in a timely manner, compromising effective protection and significantly increasing the risk of infection.

[0030] Based on in-depth observation and analysis of the numerous shortcomings of traditional face masks in actual use scenarios, such as incomplete protection, lack of active antibacterial properties, and poor wearing comfort, this invention creatively combines a multi-layered protective structure consisting of a protective layer, a filtration layer, and a skin-friendly layer with a drug-releasing device. This overcomes the limitations of traditional masks with a single function, achieving the integration of multiple functions such as protection, filtration, and antibacterial properties, providing a new, comprehensive solution for the field of antibacterial face masks.

[0031] The present disclosure provides an antibacterial mask, such as Figure 1 and Figure 2 As shown, it includes: a protective layer 1, a filter layer 2 and a skin-friendly layer 3 arranged in sequence from the outside to the inside; the protective layer 1 is used to block large particles of impurities in the external environment; the filter layer 2 is used to filter one or more harmful substances in the external environment; the skin-friendly layer 3 is used to directly contact the wearer's facial skin; a drug release device 4, the drug release device 4 is connected to the protective layer 1, the drug release device 4 has at least one drug release end 403, the drug release end 403 passes through the protective layer 1 and is arranged between the protective layer 1 and the filter layer 2, and the drug release device 4 is used to release the drug 7 between the protective layer 1 and the filter layer 2.

[0032] The protective layer 1 can be made of materials with a certain strength and durability, such as synthetic materials such as polyester fibers. Larger particles (such as dust and droplets) can be effectively blocked from entering the inside of the mask through the weaving method or material properties. The filter layer 2 can be a meltblown cloth or other high-efficiency filter material treated with an electrostatic electret, which is designed to capture smaller particles (such as PM2.5, pollen, etc.) and microorganisms. The skin-friendly layer 3 can be made of a soft, breathable material with little skin irritation, such as pure cotton, so that the wearer feels comfortable when in contact with the face. When assembling the filter layer 2 with the protective layer 1 and the skin-friendly layer 3, it is necessary to ensure that the layers are tightly fitted together. This can be achieved by edge sewing, pressing, etc. to prevent air from passing through the gaps between the layers without being filtered, affecting the filtering effect.

[0033] The drug release device 4 can be one or more small devices mounted on the protective layer 1, with a drug release end 403 extending between the protective layer 1 and the filter layer 2. The appropriate drug release device 4 is selected based on factors such as the desired properties and dosage of the drug 7 to be released. For example, if a volatile antibacterial drug is to be released, a sustained-release device with a microporous structure can be used to ensure slow and even release of the drug 7. The drug release device 4 is securely attached to the protective layer 1 through heat pressing, gluing, or other methods to ensure a secure connection and prevent it from falling off during use. Furthermore, a hole should be reserved in the protective layer 1 for the drug release end 403 to pass through.

[0034] Since the drug-releasing device 4 releases the drug 7 between the protective layer 1 and the filter layer 2, the drug 7 can form an antibacterial area between the two layers. The drug 7 diffuses in this area and can directly interact with bacteria, viruses and other microorganisms accumulated between the protective layer 1 and the filter layer 2, inhibiting or killing them, and preventing them from further penetrating the filter layer 2 to enter the skin-friendly layer 3 and subsequently contacting the wearer. Compared to ordinary masks, the antibacterial mask provided in the embodiment of the present disclosure can continuously replenish new antibacterial drugs to the area between the protective layer 1 and the filter layer 2 through the drug 7 release mechanism, maintaining a good antibacterial environment, thereby effectively extending the effective antibacterial duration of the mask and reducing the frequency of mask replacement.

[0035] In some embodiments, the drug release device 4 includes: a shell 401, which is buckled onto the surface of the protective layer 1 and forms a accommodating space with the protective layer 1; a drug storage tank 404, which is used to store the drug 7, and the drug storage tank 404 is arranged in the accommodating space and connected to the drug release end 403; a driving unit 405, which is connected to the drug storage tank 404 and is used to drive the drug 7 in the drug storage tank 404 into the drug release end 403.

[0036] The shell 401 can be made of a lightweight material with a certain strength, such as a plastic material (for example, engineering plastic), to ensure that it can be firmly fastened to the surface of the protective layer 1 without adding too much burden to the wearer. The shell 401 is a sealed container, which is fastened to the outer surface of the protective layer 1 and forms a accommodating space together with the protective layer 1. A corresponding buckle structure, a slot structure or an adhesive layer for bonding can be provided at the fastening portion between the shell 401 and the protective layer 1. For example, a plurality of elastic buckles are evenly distributed on the edge of the shell 401, and a slot is provided at the corresponding position on the protective layer 1, and a firm fastening is achieved by the close cooperation between the buckle and the slot.

[0037] The medicine storage tank 404 can be made of medical grade plastic material, such as polyethylene or polypropylene. These materials have good chemical stability, will not chemically react with the stored medicine 7, and can ensure the purity and quality of the medicine 7. The medicine storage tank 404 is located in the housing 401 and is connected to the drug release end 403. What is stored in the medicine storage tank 404 is the medicine 7 or antibacterial solution, which can be a liquid, a gas or solid particles. The specific form depends on the type of medicine 7 required to be released and its release mechanism. The medicine storage tank 404 can be closely connected to the drug release end 403 through a pipeline or other communication methods. For example, a flexible medical silicone tube can be used for communication, one end of the silicone tube is closely connected to the outlet of the medicine storage tank 404, and the other end is connected to the drug release end 403. In addition, a sealant or the like is used at the connection to prevent the leakage of the medicine 7.

[0038] The drive unit 405 can adopt a variety of drive modes. If it is necessary to accurately control the release amount and release speed of the drug 7, a micro motor can be selected as the drive unit 405. The micro motor is connected to the piston or extrusion device of the drug storage tank 404 through a transmission mechanism such as gears and screws. When the motor rotates, it drives the piston to move or the extrusion device to work, thereby pushing the drug 7 in the drug storage tank 404 into the drug release end 403 according to the set speed and amount. For some situations where high energy utilization efficiency is required and pulsed drug 7 release is required, piezoelectric ceramic drive can be used. Piezoelectric ceramics will deform when voltage is applied. Utilizing this characteristic, it can be designed to directly squeeze the drug storage tank 404 or push the elastic component connected to the drug storage tank 404 to achieve intermittent release of the drug 7.

[0039] The driving unit 405 can precisely control the amount of drug 7 in the drug storage tank 404 entering the drug release end 403 according to different application scenarios and wearer needs. Through the timed, quantitative or adjustable drug 7 release mechanism, it can continuously provide antibacterial protection during long-term wear.

[0040] In some embodiments, the shell 401 is connected to a shell cover 402 , and the shell cover 402 is detachably connected to the shell 401 , for example, by threaded connection, snap connection, etc. By removing the shell cover 402 , the medicine storage tank 404 in the shell 401 can be replenished with medicine 7 .

[0041] In some embodiments, the drug releasing device 4 further includes a connecting tube 406 , which is connected to the drug storage tank 404 and the drug releasing end 403 ; the connecting tube 406 is a flexible tube.

[0042] Connecting tube 406 can be made of medical-grade silicone hose. Medical silicone is non-toxic, odorless, and chemically stable, and will not react chemically with the delivered drug 7, thus ensuring the quality and safety of the drug 7. Based on the common dimensions of antibacterial masks, the length of connecting tube 406 can range from 5 to 15 centimeters. For example, when the drug reservoir 404 is located near one edge of the protective layer 1 and the drug release end 403 is near the center of the protective layer 1, the connecting tube 406 may need to be approximately 10 centimeters long to ensure accurate connection and not interfere with normal mask wear and use. The inner diameter size is determined based on factors such as the desired drug 7 dose to be delivered and the desired drug 7 release rate. For example, if a faster drug 7 release rate and a relatively large drug 7 dose are required, a connecting tube 406 with a larger inner diameter, such as an inner diameter between 3 and 5 mm, can be selected. If a smaller drug 7 dose is desired and a slower, more precise drug 7 release is desired, a connecting tube 406 with an inner diameter between 1 and 2 mm can be selected.

[0043] By using a flexible tube for connecting tube 406, the antibacterial mask can effectively adapt to various structural deformations caused by facial movements (such as talking, chewing, turning the head, etc.) during wear. When the protective layer 1, drug storage tank 404, or drug release end 403 undergo relative displacement due to these movements, the flexible tube can bend, stretch, or twist accordingly without breaking or affecting the normal delivery of drug 7, thus ensuring the overall structural stability of drug release device 4 and the continuity of drug 7 supply.

[0044] In some embodiments, the drug releasing end 403 is a plate-like structure, and there are multiple drug releasing ends 403 , which are evenly distributed between the protective layer 1 and the filter layer 2 ; there is a distance between the protective layer 1 and the filter layer 2 , and the distance is adapted to the thickness of the drug releasing end 403 .

[0045] The drug release end 403 has a plate-like structure, which can be a circular plate, a rectangular plate, or a polygonal plate. A material with a certain degree of flexibility and chemical stability can be selected, such as a medical-grade plastic sheet (e.g., a polycarbonate sheet) or a thin metal sheet (e.g., a stainless steel sheet, which is thin to ensure lightness and meet functional requirements).

[0046] When distributing multiple drug-releasing tips 403 evenly between the protective layer 1 and the filter layer 2, a reasonable distribution layout should be determined. A matrix layout can be employed. For example, for an antibacterial mask of appropriate size, a 3×3 or 4×4 matrix layout can be employed. This ensures that the drug-releasing tips 403 are evenly distributed within the planar space between the protective layer 1 and the filter layer 2, thereby preventing excessive or insufficient localized release of the drug 7. The drug-releasing tips 403 should be positioned away from the wearer's breathing position to prevent direct inhalation of the drug 7, which could cause unnecessary irritation or side effects, and to prevent the position of the drug-releasing tips 403 from interfering with the wearer's normal breathing.

[0047] To achieve accurate and uniform placement, the installation positions of the drug release tips 403 can be pre-marked on the protective layer 1 and the filter layer 2, and then secured to the corresponding positions using slots, snaps, or adhesives. For example, adhesive layers can be provided at corresponding positions on the protective layer 1 and the filter layer 2, and the surfaces of the drug release tips 403 can be securely mounted to the predetermined positions via the adhesive layers, ensuring their accurate placement and preventing displacement during use.

[0048] The multiple drug releasing ends 403 can be connected to the drug storage tank 404 through the connecting pipes 406 respectively, or the multiple drug releasing ends 403 can be interconnected through multiple branch pipes and then connected to the drug storage tank 404 through one connecting pipe 406 .

[0049] When assembling the protective layer 1, filtration layer 2, and drug release tip 403, a specialized mold or jig can be used to assist in controlling the spacing. For example, a jig with a specific thickness interval can be fabricated. The protective layer 1 and filtration layer 2 are then placed into the jig, initially positioning them according to the jig's defined spacing. The evenly spaced drug release tip 403 is then inserted between the protective layer 1 and filtration layer 2. Through observation and fine-tuning, the thickness of the drug release tip 403 is ensured to be perfectly aligned with the current spacing between the protective layer 1 and filtration layer 2, and the relative positions of the various components are accurate.

[0050] Since there are multiple drug-releasing ends 403 evenly distributed between the protective layer 1 and the filter layer 2, it is possible to achieve full coverage of the area between the protective layer 1 and the filter layer 2. The drug 7 is released simultaneously from each drug-releasing end 403, forming a relatively uniform drug 7 distribution environment between the two layers, avoiding the situation where the local drug 7 concentration is too high or too low due to only a single drug-releasing point, thereby ensuring that the antibacterial drug can act evenly on areas where harmful microorganisms such as bacteria and viruses may exist, thereby improving the uniformity and comprehensiveness of the antibacterial effect. The spacing between the protective layer 1 and the filter layer 2 is adapted to the thickness of the drug-releasing end 403. By reasonably setting the spacing and the thickness of the drug-releasing end 403, the drug 7 release device is integrated into the mask structure, so that the entire mask can achieve the antibacterial function without affecting its original protection and filtering functions, and is more reasonable and efficient in space utilization.

[0051] In some embodiments, the drug release device 4 also includes a detection unit 407 and a control unit 408. The detection unit 407 is arranged between the protective layer 1 and the filter layer 2. The detection unit 407 is used to detect the concentration of viruses or bacteria between the protective layer 1 and the filter layer 2; the control unit 408 is respectively communicated with the detection unit 407 and the driving unit 405, and the control unit 408 controls the start and stop of the driving unit 405 according to the detection results of the detection unit 407.

[0052] The detection unit 407 can use a suitable biosensor to detect the concentration of viruses or bacteria between the protective layer 1 and the filter layer 2. For example, a biosensor based on optical principles can be used, which uses the absorption, scattering or fluorescence characteristics of microorganisms to specific wavelengths of light to identify and quantify the concentration of microorganisms. Alternatively, a biosensor based on electrochemical principles can be used to detect the presence and concentration of microorganisms through the electrochemical reaction between microorganisms and the electrode surface. The detection unit 407 must be accurately set between the protective layer 1 and the filter layer 2 to obtain the most accurate information on the concentration of viruses or bacteria in the area. Special installation slots can be reserved at the corresponding positions of the protective layer 1 and the filter layer 2, and the sensor part of the detection unit 407 can be embedded in the installation slot. It can be ensured that its position is stable by gluing, fixing with a card slot, etc., and will not shift due to daily use of the mask (such as the wearer talking, turning the head, etc.), affecting the accuracy of the detection results.

[0053] Setting an appropriate testing frequency should be based on factors such as the wearer's usage habits and the likelihood of environmental changes. For example, during the initial wear period, a higher testing frequency, such as every few minutes, can be set to quickly assess the initial microbial status between protective layer 1 and filter layer 2. As wear time increases, the testing frequency can be appropriately reduced, such as every half hour or hour, to reduce unnecessary energy consumption and data transmission.

[0054] Detection unit 407 transmits the detected virus or bacteria concentration data to control unit 408 in real time. Data transmission can be carried out by wired means (e.g., using a thin flexible wire connection, which must be well insulated and stretch-resistant) or wireless means (e.g., using wireless communication technologies such as low-power Bluetooth and ZigBee) to ensure the stability and timeliness of data transmission, so that control unit 408 can make accurate decisions based on the latest data.

[0055] Control unit 408 can utilize a small microcontroller, such as the common ARM Cortex-M series. These microcontrollers offer advantages such as compact size, low power consumption, and high processing power, making them suitable for integration into small devices like antibacterial masks. The appropriate chip model and corresponding memory, storage, and other resources should be selected based on factors such as the amount of data to be processed and the complexity of the control logic.

[0056] In order to achieve communication connection with the detection unit 407 and the drive unit 405, the control unit 408 needs to be equipped with a corresponding communication interface. For the connection with the detection unit 407, if wireless communication is adopted, a wireless communication interface such as a Bluetooth module or a ZigBee module needs to be equipped; if a wired communication method is adopted, a suitable general input and output (GPIO) interface needs to be set to receive data from the detection unit 407. For the connection with the drive unit 405, control instructions can be sent through the GPIO interface or a dedicated motor control interface (if the drive unit 405 is motor-driven) to achieve start and stop control of the drive unit 405.

[0057] The control unit 408 runs specific control logic and algorithms, and decides whether to start or stop the drive unit 405 based on the virus or bacteria concentration data transmitted by the detection unit 407. For example, a virus or bacteria concentration threshold is set. When the virus or bacteria concentration detected between the protective layer 1 and the filter layer 2 exceeds the threshold, the control unit 408 issues a command to start the drive unit 405, prompting the drug 7 in the drug storage tank 404 to be released through the drug release end 403 into the space between the protective layer 1 and the filter layer 2, thereby enhancing the antibacterial effect. When the concentration is detected to be below the threshold, the control unit 408 issues a command to stop the drive unit 405, avoiding unnecessary release of the drug 7 and conserving drug 7 resources.

[0058] The detection unit 407 detects the concentration of viruses or bacteria between the protective layer 1 and the filter layer 2 in real time, and the control unit 408 accurately controls the start and stop of the drive unit 405 based on the detection results, thereby achieving the on-demand release of the drug 7. As the wearer's environment changes (such as from a clean environment to a polluted environment, or vice versa) and the wearing time increases, the concentration of viruses or bacteria between the protective layer 1 and the filter layer 2 will also change. This setting can monitor these changes in real time and dynamically adjust the drug 7 release strategy based on the changes. For example, when the wearer enters a highly polluted environment and the concentration of viruses or bacteria rises rapidly, the control unit 408 can promptly start the drive unit 405 to increase the release of the drug 7; when leaving the highly polluted environment and the concentration drops, the control unit 408 can promptly stop or reduce the release of the drug 7, so that the antibacterial mask can dynamically adapt to environmental changes and always maintain a good antibacterial effect.

[0059] In some embodiments, the filter layer 2 includes a first antibacterial layer, a second antibacterial layer, and a third antibacterial layer that are stacked; the first antibacterial layer is arranged close to the protective layer 1, and the first antibacterial layer is made of an antibacterial material containing copper ions; the second antibacterial layer is located between the first antibacterial layer and the third antibacterial layer, and the second antibacterial layer is made of a material containing nanosilver; the third antibacterial layer is arranged close to the skin-friendly layer 3, and the third antibacterial layer is made of a material containing natural plant antibacterial extracts.

[0060] The first antibacterial layer can be made of copper ion-containing fiber raw materials with good antibacterial properties and suitable for making into fabric sheets. These raw materials can be made by adding copper ion compounds during the synthesis process of conventional fibers (such as polyester fibers, cotton fibers, etc.) to have antibacterial properties.

[0061] Specifically, taking polyester fiber synthesis as an example, a reaction solution containing monomers (such as terephthalic acid and ethylene glycol) must first be prepared. To this solution system, the selected copper ion compound is added in a certain proportion. The amount added is determined based on factors such as the desired antibacterial properties and the specifications of the final fiber product. After the copper ion compound is added to the fiber synthesis solution, it is necessary to ensure that it is evenly mixed in the solution, which can be achieved by stirring or other methods.

[0062] During the polymerization reaction of fiber synthesis, as the polymerization reaction between monomers gradually forms a polymer chain, the added copper ion compound will participate in this process. Taking polyester fiber as an example, during the condensation reaction of terephthalic acid and ethylene glycol to form a polyester chain, copper ions will be combined with the forming polyester chain through chemical bonds or physical adsorption. For example, copper ions may react chemically with certain functional groups on the polyester chain (such as carboxyl, hydroxyl, etc.) to form stable chemical bonds, thereby fixing the copper ions inside the fiber. Alternatively, copper ions may also be adsorbed around the polyester chain through physical effects such as electrostatic attraction, and be wrapped inside the fiber as the fiber is formed.

[0063] After the fiber is formed, there may be some unreacted copper ion compounds or other impurities attached to the fiber surface, which need to be washed and purified. The fiber can be washed with a suitable solvent (such as clean water, mild organic solvent, etc.) to remove surface impurities. The washed fiber needs to be dried to restore the fiber to a normal moisture content. The drying process can be carried out by natural drying, oven drying, etc. During the drying process, attention should be paid to controlling conditions such as temperature and humidity to avoid excessively high temperatures causing fiber deformation or unnecessary chemical reactions of copper ions. At the same time, in order to ensure that the antibacterial properties of copper ions in the fiber can be stable for a long time, some stabilization treatments can be carried out after drying, such as by adding a small amount of additives (such as antioxidants, anti-ultraviolet agents, etc.) to protect the fiber and the copper ions therein to prevent them from being affected by external environmental factors (such as oxidation, ultraviolet radiation, etc.) and reducing the antibacterial properties.

[0064] Finally, the copper-ion-containing fiber raw materials are processed through a textile process to form fabric sheets. This process includes carding, spinning, and weaving the fibers. The fabric sheets must have an appropriate density to ensure good breathability while fully utilizing the antibacterial properties of the copper ions. Furthermore, the fabric sheets must be quality-tested to ensure that the copper ion content is within the effective antibacterial range and that the fabric's physical properties, such as strength and flexibility, meet the required standards.

[0065] Through the above steps, a copper ion-containing fiber raw material that can be used to make the first antibacterial layer of an antibacterial mask and other applications is finally obtained.

[0066] The second antibacterial layer can select nano silver particles with high purity and appropriate particle size as the basic material for making the film.

[0067] Specifically, the plastic sheet with certain pore structure can be selected as substrate material, and as polytetrafluoroethylene (PTFE) porous film, it itself has good air permeability, can allow gas molecules to diffuse by its micropore. This material, when forming antibacterial film as substrate-carrying nano silver particles, can provide certain air permeability channel for overall film. In addition, some non-woven materials also can be used as substrate after special treatment, and the fiber interwoven structure of non-woven fabrics can form certain space, is conducive to gas circulation. Select the non-woven fabric with good air permeability, and make containing nano silver film thereon, can realize good air permeability when guaranteeing antibacterial property.

[0068] The particle size of the nanosilver particles can be controlled between 1 and 100 nanometers to ensure good antimicrobial activity and stability. Chemical synthesis methods can be used to prepare nanosilver particles, such as reducing a silver salt solution to form nanosilver particles through a reduction reaction. These particles are then purified and dispersed to allow for uniform dispersion in a suitable solvent for subsequent film production. The solution containing the nanosilver particles is thoroughly stirred to ensure uniform distribution of the particles throughout the solution, without precipitation or agglomeration.

[0069] Using a pipette or dropper, evenly drip an appropriate amount of the solution containing dispersed silver nanoparticles onto the surface of the selected substrate. The amount of solution should be controlled based on factors such as the size of the substrate and the desired film thickness. It is generally advisable to evenly cover the surface of the substrate and prevent overflow during subsequent rotation.

[0070] Place the substrate with the solution added onto a spin coater and set the appropriate rotation speed and time parameters. Once the spin coater is turned on, the substrate begins to spin. Under the influence of centrifugal force, the solution applied to the surface spreads evenly, gradually forming a thin film. The rotation speed and time settings should be considered based on factors such as the concentration of the silver nanoparticles, the volatility of the solvent, and the desired film thickness. Generally, the rotation speed can be adjusted between several hundred and several thousand revolutions per minute, and the rotation time can range from several seconds to tens of seconds.

[0071] After rotation is completed, the film obtained also contains solvent composition, needs to carry out drying process to remove solvent, makes film solidification.The base material with film can be placed in a well-ventilated environment and naturally dry, or in a low-temperature baking oven, carry out drying process (temperature will be controlled in the scope that can not destroy nano silver particles and film structure, generally no more than the boiling point of solvent).After processing such as drying, solidification, can obtain containing nano silver film.

[0072] The third antibacterial layer first screens natural plants with significant antibacterial activity, such as tea trees, lavender, and mugwort. Then, effective antibacterial ingredients are extracted from these plants using extraction techniques such as solvent extraction and supercritical fluid extraction.

[0073] Specifically, tea plants, such as the tea tree, are widely cultivated in some regions. Their extract, tea polyphenols, has excellent antibacterial effects and is relatively safe, making it a common choice. Fresh or dried tea leaves are selected and crushed into an appropriate particle size, typically using a grinder or other equipment to form a powder or fine particles. This increases the contact area with the solvent and improves extraction efficiency.

[0074] Next, the antimicrobial components are extracted. An appropriate organic solvent, such as ethanol, is selected based on the properties of the antimicrobial components present in the tea plant. Ethanol has excellent solubility and can dissolve tea polyphenols and other antimicrobial components in the tea plant. It is also relatively safe and volatile, making it easy to handle later. The crushed tea plant material is placed in a suitable extraction container and an appropriate amount of ethanol solvent is added to completely immerse the material in the solvent. The container is then sealed and placed at a suitable temperature for extraction. The extraction temperature can generally be set between 20°C and 60°C. Stirring or oscillating the material allows for full contact with the solvent, promoting the dissolution of the antimicrobial components. The extraction time varies depending on the specific situation, typically ranging from a few hours to several dozen hours, for example, 8 to 24 hours. After extraction is complete, the extract is separated from the solid residue using a filtration device (such as filter paper, a filter screen, or a filter funnel) to produce an ethanol solution containing tea polyphenols and other antimicrobial components.

[0075] Alternatively, a fluid in a supercritical state (such as supercritical carbon dioxide) can be used as an extractant. Supercritical fluids have special properties such as gas-like diffusivity and liquid-like solubility, and can efficiently extract antibacterial ingredients from natural plants. First, the natural plant raw materials are pretreated (such as crushing, etc.), then placed in a supercritical fluid extraction device, and the equipment parameters are adjusted to make the fluid reach a supercritical state. The extraction operation is performed under specific pressure, temperature and other conditions. After the extraction is completed, the extracted antibacterial ingredients are separated from the supercritical fluid by means of decompression or other methods.

[0076] Whether the antimicrobial extract solution is obtained through solvent extraction or supercritical fluid extraction, it requires concentration to increase the concentration of antimicrobial components and make it more suitable for coating production. Solutions extracted with organic solvents such as ethanol can be concentrated using vacuum distillation. The extract is placed in a vacuum distillation apparatus, where the system pressure is reduced, causing the solvent to boil and evaporate at a lower temperature, thereby concentrating the solution.

[0077] The concentrated antimicrobial extract may still contain some impurities and needs to be purified to improve its purity and activity to meet the requirements for coating production. The purification method can be selected according to the specific situation, such as column chromatography, membrane separation, etc. Taking column chromatography as an example, the concentrated antimicrobial extract solution is passed through a chromatography column filled with a specific adsorbent (such as silica gel, alumina, etc.). The different components are separated in the column according to their adsorption and desorption characteristics with the adsorbent, thereby removing impurities and obtaining an antimicrobial extract of higher purity.

[0078] Select an appropriate film-forming agent based on the coating's performance requirements (such as flexibility, breathability, and compatibility with the substrate). Common film-forming agents include polyvinyl alcohol (PVA) and acrylic resins. For example, PVA has good water solubility, flexibility, and a certain degree of breathability, making it suitable for coatings that come into contact with human skin and require a certain degree of comfort. Acrylic resins, on the other hand, offer excellent weather resistance, chemical stability, and adhesion, and can be selected based on the specific application scenario.

[0079] The concentrated and purified natural plant antimicrobial extract is mixed with the selected film-forming agent in a specific ratio. This ratio is determined based on factors such as the activity of the antimicrobial component, the properties of the film-forming agent, and the final coating requirements. Generally, the two are thoroughly mixed in a suitable solvent (such as dehydrated water or ethanol, depending on the solubility of the film-forming agent) by stirring to form a uniform antimicrobial coating solution.

[0080] The substrate material should be a thin, lightweight material that matches the second antibacterial layer. For example, if the second antibacterial layer is made of a plastic film, the substrate material can be a plastic sheet or non-woven fabric that is compatible with the film, has a smooth surface, and has a certain degree of air permeability.

[0081] Next, the coating is applied using a spraying method. The antimicrobial coating solution is loaded into a spray gun and the parameters, such as spray pressure, spray angle, and distance between the nozzle and the substrate, are adjusted. The spray pressure is typically set between 0.1 and 0.5 MPa, the spray angle is adjusted based on the desired coverage area and shape, and the distance between the nozzle and the substrate can be between 10 and 30 cm. The substrate is then placed on a suitable work surface and the spray gun is activated to evenly spray the antimicrobial coating solution onto the surface.

[0082] Alternatively, use a brushing method: Use a suitable brush (such as a soft-bristle brush or nylon brush), dip an appropriate amount of the antibacterial coating solution into the surface of the substrate, and evenly apply it to the surface of the substrate. When applying, be sure to apply evenly and in a certain direction and order, such as from one end to the other or from top to bottom, to ensure uniformity of the coating.

[0083] Through the above detailed steps, a third antibacterial layer that meets the requirements can be produced to provide effective antibacterial protection for the antibacterial mask while taking into account the wearer's comfort and the breathability of the mask.

[0084] The three layers are stacked in this order: the first antimicrobial layer is positioned adjacent to the protective layer 1, the second antimicrobial layer is positioned in the middle, and the third antimicrobial layer is positioned adjacent to the skin-friendly layer 3. The three layers can be assembled together using methods such as heat pressing, gluing, or sewing. For example, heat pressing involves stacking the three layers in sequence and placing them in a specialized heat press. Heat pressing is performed under appropriate temperature, pressure, and time conditions to ensure a tight fit between the layers, forming a single, integrated filter layer 2.

[0085] Because filter layer 2 comprises three distinct antimicrobial layers—a copper-ion-containing antimicrobial fabric sheet, a nanosilver film, and a coating containing natural plant antimicrobial extracts—then forms a comprehensive antimicrobial protection system. The different antimicrobial layers have distinct antimicrobial mechanisms. The copper-ion-containing antimicrobial fabric sheet primarily achieves its antimicrobial effect by interacting with proteins and other components of microbial cell membranes, disrupting the membrane structure. The nanosilver film utilizes various biochemical reactions between nanosilver particles and microorganisms, such as disrupting microbial respiration and DNA replication, to exert its antimicrobial effect. The coating containing natural plant antimicrobial extracts relies on the interaction between the active ingredients in the plant extracts and microorganisms. These complementary antimicrobial mechanisms ensure a long-lasting antimicrobial effect. Even during extended wear, microorganisms attempting to penetrate the various antimicrobial defenses will be hindered by the continuous action of the different antimicrobial layers, thus providing the wearer with long-lasting antimicrobial protection.

[0086] In some embodiments, the antimicrobial mask further comprises:

[0087] The isolation layer 5 is arranged between the filter layer 2 and the skin-friendly layer 3 . The isolation layer 5 is used to prevent the drug 7 from contacting the skin-friendly layer 3 .

[0088] The isolation layer 5 must be made of a material with excellent barrier properties to effectively prevent the drug 7 from penetrating between the skin-friendly layer 3 and the filter layer 2. For example, a medical-grade polyurethane film can be used, which has low air permeability and high barrier properties, effectively preventing drug 7 molecules and other possible tiny particles from penetrating. Alternatively, a polytetrafluoroethylene (PTFE) film can be selected, which has extremely excellent barrier properties and can almost completely block the penetration of the drug 7. It also has high chemical stability and will not chemically react with the drug 7 or other substances, thus reliably achieving its isolation function. The isolation layer 5 should be large enough to completely cover the contact area between the filter layer 2 and the skin-friendly layer 3, ensuring that there are no gaps for the drug 7 to pass through.

[0089] The isolation layer 5 can be installed between the filter layer 2 and the skin-friendly layer 3 by gluing. Select a medical adhesive that is compatible with the materials of the isolation layer 5, filter layer 2, and skin-friendly layer 3. First, evenly apply adhesive to one side of the isolation layer 5 and accurately attach it to the side of the filter layer 2 facing the skin-friendly layer 3. Apply appropriate pressure to ensure a tight fit between the isolation layer 5 and the filter layer 2. Next, apply adhesive to the other side of the isolation layer 5 and attach the skin-friendly layer 3 to the isolation layer 5. Again, apply pressure to ensure that the three layers are firmly bonded and form a single, integrated whole.

[0090] The isolation layer 5 prevents the drug 7 from coming into contact with the skin layer and the filter layer 2, thereby preventing the drug 7 from directly contacting the wearer and irritating the wearer, thereby improving the safety and comfort of wearing. At the same time, the presence of the isolation layer 5 more precisely limits the active area of ​​the drug 7 to the area between the protective layer 1 and the filter layer 2. This helps to improve the utilization efficiency of the drug 7, because the drug 7 does not diffuse into unwanted areas (such as between the skin-friendly layer 3 and the filter layer 2). Instead, it is concentrated in the area where the antibacterial effect is most needed, that is, between the protective layer 1 and the filter layer 2, thereby more effectively inhibiting or killing bacteria, viruses, and other microorganisms that may be present in this area.

[0091] In some embodiments, the antibacterial mask further includes: a plurality of connecting parts 6, the connecting parts 6 are rod-shaped and made of fiber material, and the two ends of the connecting parts 6 are respectively connected to the protective layer 1 and the filter layer 2; the plurality of connecting parts 6 are evenly distributed between the protective layer 1 and the filter layer 2, and the connecting parts 6 are arranged to avoid the range where the drug release end 403 is located.

[0092] The connecting portion 6 is made of a fiber material into a rod-shaped structure, preferably fibers with a certain strength, flexibility, and chemical stability. For example, polyester fiber has good mechanical properties and can withstand a certain amount of tension and pressure, ensuring that it will not easily break when connecting the protective layer 1 and the filter layer 2. At the same time, polyester fiber is chemically stable and will not chemically react with the drug 7 or other substances in the antibacterial mask, thereby ensuring the overall performance and safety of the mask. Alternatively, nylon fiber can be used. Nylon fiber has high strength and outstanding flexibility. When making the rod-shaped connecting portion 6, it can better adapt to various deformations of the mask during wearing, such as the relative displacement between the protective layer 1 and the filter layer 2 caused by the wearer talking, turning the head, etc. The selected fiber material is processed into a rod shape. The fiber can be first made into yarn through a textile process, and then the yarn is made into a rod-shaped structure with a certain diameter and length by braiding or winding.

[0093] Multiple connecting portions 6 need to be evenly distributed between the protective layer 1 and the filtration layer 2. A matrix or annular distribution can be employed. If a matrix distribution is employed, the number of rows and columns of the matrix can be appropriately determined based on the area of ​​the protective layer 1 and the filtration layer 2. If an annular distribution is employed, the connecting portions 6 can be arranged in a ring-like pattern around a central point (e.g., the center area of ​​the protective layer 1 and the filtration layer 2) at regular angular intervals to ensure that the distances between the connecting portions 6 are relatively uniform.

[0094] When designing the layout of the connector 6, it is necessary to avoid the area where the drug release end 403 is located. A certain distance should be maintained between the connector 6 and the drug release end 403 to avoid interfering with the drug release function of the drug release end 403. For example, the minimum distance between the connector 6 and the edge of the drug release end 403 can be set to a few millimeters (e.g., 3-5 mm) to ensure that the drug 7 can be smoothly released from the drug release end 403 into the space between the protective layer 1 and the filtration layer 2 without being blocked by the connector 6 or affecting its diffusion path.

[0095] One end of the connector 6 is fixed to the protective layer 1, and the other end is fixed to the filter layer 2, thus achieving a connection between the protective layer 1 and the filter layer 2. Common fixing methods include gluing and hot-melt bonding. If gluing is used, an adhesive that is compatible with the materials of the protective layer 1, the filter layer 2, and the connector 6 should be selected. An appropriate amount of adhesive is applied to each end of the connector 6, and then it is accurately affixed to the corresponding positions of the protective layer 1 and the filter layer 2, applying appropriate pressure to ensure a secure adhesion. For the hot-melt bonding method, a heating device can be used to heat the ends of the connector 6 to a certain temperature, respectively, at the connector 6 positions of the protective layer 1 and the filter layer 2, so that the materials partially melt and fuse together. After cooling, a secure connection is formed. The connectors 6 are evenly distributed and made of fiber material, so they do not significantly hinder the flow of air between the protective layer 1 and the filter layer 2. The gaps between the connectors 6 and the relatively small diameter of the connectors 6 themselves provide air circulation channels, ensuring the breathability of the mask.

[0096] Due to the provision of multiple drug-releasing ends 403, a certain distance is required between the protective layer 1 and the filter layer 2. The connecting portion 6 is evenly distributed between the protective layer 1 and the filter layer 2 with its rod-shaped structure, just like building an invisible support frame. They are responsible for stably holding the protective layer 1 and the filter layer 2 apart, so that the specific spacing between the two layers required by the provision of the drug-releasing end 403 can be accurately maintained. No matter what kind of squeezing, stretching or twisting actions the wearer performs on the mask during daily activities, the connecting portion 6 can rely on its own toughness and strength to resist the influence of these external forces, prevent the protective layer 1 and the filter layer 2 from being squeezed to the drug-releasing end 403 due to being too close, thereby avoiding interference with the normal operation of the drug-releasing device 4 and ensuring the continuous and stable performance of the drug-releasing function.

[0097] While ensuring the distance between the protective layer 1 and the filter layer 2, the gap between the connecting parts 6 also forms a natural channel for air circulation. Air can flow smoothly between the two layers along these channels, so that the gas exhaled by the wearer can be discharged in time and fresh air from the outside can also enter smoothly. This good air circulation, on the one hand, improves the wearer's breathing comfort and avoids the stuffiness and suffocation caused by air stagnation; on the other hand, it also helps to maintain the performance of the protective layer 1 and the filter layer 2 themselves. For example, for the filter layer 2, continuous air circulation can ensure that it always filters and purifies the air entering the mask in the best condition, effectively intercepting harmful substances such as bacteria, viruses, dust, etc. in the air, and the protective layer 1 can also better play its initial protective function of blocking large particles of impurities in an air circulation environment.

[0098] In some embodiments, as Figure 3 As shown, multiple connecting parts 6 are located on the surface of the filter layer 2 to form a pair of oppositely arranged accommodating areas, and the pair of accommodating areas are respectively arranged corresponding to the cheek sides of the wearer. Each accommodating area is used to place a drug releasing end 403, and the size of the accommodating area is adapted to the drug releasing end 403; the drug releasing end 403 is respectively contacted with the filter layer 2 and the protective layer 1 on both side surfaces along its thickness direction, and the drug releasing end 403 is provided with multiple through holes 409 along the circumferential side surface perpendicular to the thickness direction, and the drug 7 enters between the multiple connecting parts 6 through the through holes 409; the drug 7 is in any of the forms of mist, particles or liquid.

[0099] By adjusting the arrangement and spacing of the connecting portions 6, a precisely shaped accommodation area is created to match the dimensions of the drug-releasing end 403. The connecting portions 6 can be arranged at equal intervals, for example, with spacing between 3-8 mm. This ensures a secure connection between the connecting portions 6 and the protective layer 1 and the filter layer 2, while also leaving an appropriate amount of space between adjacent connecting portions 6 to form an accommodation area. The length and width of the accommodation area can be slightly larger than the corresponding dimensions of the drug-releasing end 403 by 2-5 mm to facilitate placement and subsequent fine-tuning of the drug-releasing end 403. This also ensures that the drug-releasing end 403 does not shift within the accommodation area due to being too loose, nor is it too compact to be difficult to install or affect its normal function. By adapting the size of the accommodating area to the drug releasing end 403, the connecting portion 6 around the drug releasing end 403 can provide support for the peripheral side of the drug releasing end 403, and the protective layer 1 and the filter layer 2 are combined to clamp the two side surfaces of the drug releasing end 403, so that the drug releasing end 403 can be stably arranged between the protective layer 1 and the filter layer 2 without the need for other fixing methods, which is convenient for processing.

[0100] A plurality of through holes 409 are provided along the peripheral surface perpendicular to the thickness direction of the drug release end 403. The design of the through holes 409 is determined according to the state of the drug 7 (mist, granules or liquid) and the desired drug 7 release effect.

[0101] For the mist drug 7, the through hole 409 can be relatively small, for example, with a diameter between 0.1 and 0.5 mm, to control the release speed and direction of the mist drug 7 and prevent it from spreading too quickly or concentrating in a certain area. The shape of the through hole 409 can be designed to be circular, which is convenient for processing and can make the mist drug 7 spray out more evenly. When the drug 7 is in mist form, the driving unit 405 pushes the drug 7 in the drug storage tank 404 so that it reaches the drug release end 403 through the connecting pipe 406. Inside the drug release end 403, the drug 7 exists in the form of mist. Due to the certain pressure inside the drug release end 403 (provided by the driving unit 405), the mist drug 7 will be evenly sprayed into the space between the multiple connecting parts 6 through the through holes 409 on the circumferential side. The mist drug 7 has good diffusivity and can quickly spread between the connecting parts 6 to form a relatively uniform distribution environment of the drug 7, so as to have an antibacterial effect on microorganisms such as bacteria and viruses that may exist between the protective layer 1 and the filter layer 2.

[0102] If the medicine 7 is granular, the diameter of the through hole 409 needs to be adjusted according to the particle size, generally slightly larger than the particle diameter. For example, when the particle diameter is 0.5-1 mm, the diameter of the through hole 409 can be set between 0.6-1.2 mm to ensure that the particles can pass through the through hole 409 smoothly without clogging. The shape of the through hole 409 can be circular or square. The square through hole 409 may be more conducive to the orderly discharge of particles in some cases. For granular medicine 7, it is also driven by the drive unit 405 and transported to the drug release end 403 through the connecting pipe 406. After arriving at the drug release end 403, the granular medicine 7 relies on its own gravity and the slight vibration that may exist inside the drug release end 403 (which can be achieved by setting a tiny vibration device at the drug release end 403, such as a micro vibration motor, etc., to help the particles to be discharged smoothly), and is discharged one by one from the through hole 409 on the side and enters between the multiple connecting parts 6.

[0103] When the drug 7 is in liquid form, the size of the through hole 409 should also be considered based on factors such as the viscosity of the liquid. If it is a low-viscosity liquid, the diameter of the through hole 409 can be between 0.2-0.8 mm; for high-viscosity liquids, a slightly larger through hole 409 may be required, such as a diameter between 0.5-1.5 mm. The shape of the through hole 409 can be circular or elliptical. The elliptical through hole 409 helps the liquid to flow out evenly in different directions. Driven by the drive unit 405, the liquid drug 7 reaches the drug release end 403 through the connecting tube 406. Inside the drug release end 403, the liquid drug 7 will flow out from the through hole 409 on the circumferential side under the action of pressure (such as by setting an elastic diaphragm or other device at the drug release end 403 to control the liquid pressure and ensure that the liquid can flow out smoothly) and enter between the multiple connecting parts 6. Due to the fluidity of the liquid, it will flow and diffuse in the space between the connecting parts 6.

[0104] Through-holes 409 should be evenly distributed around the drug release tip 403, and can be arranged in a circular array or other arrangement. For example, for a smaller drug release tip 403, 8-16 through-holes 409 can be evenly distributed around the tip; for a larger drug release tip 403, the number of through-holes 409 can be increased to 16-32 to ensure relatively uniform release of drug 7 from all directions. High-precision machining methods such as laser drilling can be used to ensure the accuracy and surface smoothness of through-holes 409, avoiding drug 7 residue or clogging of through-holes 409 due to rough machining.

[0105] By setting a pair of accommodating areas precisely corresponding to the cheeks of the wearer and placing the drug-releasing ends 403 in these two accommodating areas, the drug 7 is prevented from being released directly toward the wearer's mouth and nose. After the drug 7 is sprayed out from each drug-releasing end 403, the multiple connecting parts 6 are evenly distributed between the protective layer 1 and the filter layer 2, and the space formed by them provides a uniform diffusion path for the drug 7. When the wearer breathes, the exhaled and inhaled air will flow, and the drug 7 molecules can use this air flow situation, combined with their own diffusion characteristics, to spread evenly to the surroundings in the space like a "diffusion network" constructed by the connecting parts 6. In this way, the drug 7 is fully covered in the entire space between the protective layer 1 and the filter layer 2.

[0106] By positioning a pair of drug-releasing ends 403 corresponding to the cheeks of the wearer, and providing multiple connecting portions 6, the drug 7 can be evenly distributed to every corner where microorganisms may breed, allowing the drug 7 to fully exert its antibacterial effect and improving the utilization efficiency of the drug 7. This effectively avoids excessive concentration of the drug 7 in a local area, thereby preventing the possibility of adverse effects on the protective layer 1 or the filter layer 2 materials due to excessive drug 7 concentration.

[0107] In some embodiments, the air permeability of the protective layer 1 is greater than that of the filter layer 2 , the drug 7 is in granular form, and the drug 7 can be vaporized under temperature changes.

[0108] Drug 7 can be chlorine dioxide granules. Chlorine dioxide is a highly effective disinfectant and is often formulated into granules for easier storage and use. It is relatively stable at room temperature and appears as white or slightly yellow granules. Chlorine dioxide has a powerful killing effect on a wide range of microorganisms, including bacteria, viruses, and fungi. It can destroy microbial cell walls, cell membranes, and internal biomacromolecules such as proteins and nucleic acids, thereby inactivating the microorganisms and achieving the purpose of disinfection and sterilization. In the mask environment, it can effectively kill various pathogenic microorganisms attached to the protective layer 1 and filter layer 2, as well as those that may be present in the air, significantly reducing the risk of infection for the wearer. Chlorine dioxide granules typically undergo a gasification transformation at temperatures close to or slightly above room temperature. Generally speaking, at temperatures around 15-30°C, it gradually transforms from granular to gaseous. The temperature of human exhaled air (around 30-37°C) is sufficient to facilitate this transformation within the mask. In the application of antibacterial masks, the concentration of chlorine dioxide granules is generally controlled between 0.05% and 0.2%, which is more suitable. Within this concentration range, it can not only effectively kill various pathogenic microorganisms in the protective layer 1, the filter layer 2 and the air inside the mask, but also ensure that its concentration is within a reasonable range when it vaporizes and diffuses, and will not cause obvious irritation or damage to the wearer's respiratory tract, eyes and other sensitive parts.

[0109] Drug 7 can also be made from particles of mugwort essential oil. Mugwort essential oil is a natural ingredient extracted from mugwort leaves and processed into granules. These granules are typically light yellow or light green and have the unique fragrance of mugwort. Mugwort essential oil particles have a relatively low boiling point and can transform from granules to a gaseous state within the temperature range of human exhaled air. Typically, they achieve good volatilization and diffusion at around 25-35°C, completing the vaporization process within the mask. Mugwort essential oil has certain antibacterial and antiviral properties. Studies have shown that it can inhibit the growth and reproduction of various bacteria and viruses. While its disinfection and sterilization capabilities may not be as strong as those of the chemical disinfectants mentioned above, it can still play a significant auxiliary role in reducing the number of microorganisms that may breed inside the mask in daily protective situations. When used in antibacterial masks, the appropriate concentration range of mugwort essential oil particles is generally 0.1%-0.5%. Within this concentration range, it can inhibit the growth and reproduction of common bacteria and viruses, effectively reducing the number of microorganisms that may breed inside the mask. Moreover, as a natural plant extract, it poses minimal harm to the human body at this concentration. It can also relieve the stuffiness of wearing a mask by emitting a refreshing scent, thereby improving the wearer's comfort.

[0110] The protective layer 1 can be made of a material with a high porosity, such as a porous non-woven fabric or a plastic film with a microporous structure. The pore size and distribution of these materials should ensure good air permeability, allowing air to pass through quickly, while also preventing large particles of impurities from entering the mask.

[0111] After the drug release end 403 releases the granular drug 7, due to its light weight, when the wearer breathes or exercises, the flow of air and the resulting vibration will cause the drug 7 to shuttle between the protective layer 1 and the filter layer 2, and can move around the multiple connecting parts 6. During this process, the drug 7 can sterilize and disinfect the protective layer 1, the filter layer 2, and the connecting parts 6. As the wearer continues to breathe, the exhaled gas of the human body continuously causes temperature changes. This temperature change will cause the drug 7 particles to continue to vaporize, and then continuously replenish the space between the protective layer 1 and the filter layer 2. The vaporized drug 7 exists in the form of gas. Due to its gaseous properties, it can quickly diffuse in the space between the protective layer 1 and the filter layer 2, achieving comprehensive coverage of this area, and even some gaps and blind spots where bacteria, viruses and other microorganisms may breed will not be missed.

[0112] It takes a certain amount of time for the drug 7 to be completely transformed from granular gasification to gas. This process enables the bactericidal and disinfecting effect of the drug 7 to continue to be exerted for a relatively long period of time, effectively extending the bactericidal and disinfecting time of the drug 7.

[0113] If the drug 7 remains in particulate form, some particles may remain on the mask surface or accumulate between the protective layer 1 and the filter layer 2. This not only affects the mask's appearance but can also cause problems for the wearer, such as skin irritation. However, the vaporized drug 7 exists and diffuses as a gas, leaving virtually no visible drug 7 residue. This keeps the mask clean and effectively avoids any adverse effects on the wearer from residual drug 7, further enhancing the wearer's experience.

[0114] In addition, since the air permeability of the protective layer 1 is greater than that of the filter layer 2, and the drug 7 is easily vaporized, when the wearer breathes, the vaporized drug 7 is more easily discharged from the outside of the mask along the protective layer 1 with good air permeability. In contrast, it is not easy for the drug 7 gas to pass through the filter layer 2 with relatively poor air permeability and enter the wearer's mouth and nose. After the drug 7 is vaporized, most of the gas will diffuse out of the protective layer 1 with the flow of air. Even if a very small amount of drug 7 may pass through the filter layer 2, as long as its concentration is within the specified range, it will not cause harm to the human body even if it enters the mouth and nose. Through the above-mentioned comprehensive utilization of the granular characteristics of the drug 7 and the air permeability characteristics of the protective layer 1 and the filter layer 2, the antibacterial mask can take into account the wearer's user experience and health and safety while ensuring the sterilization and disinfection effect.

[0115] In some embodiments, as Figure 4 As shown, the antibacterial mask further comprises a protective cover 8 .

[0116] The protective cover 8 is made of a transparent acrylic material and can be detachably connected to the shell cover 402, such as by snapping. This detachable connection design greatly facilitates the cleaning and maintenance of the protective cover 8. When the surface of the protective cover 8 is contaminated with dust or stains during use, or when it needs to be disinfected for hygiene reasons, the operation is very simple. Simply remove the protective cover 8 from the shell cover 402, and then you can clean, wipe or disinfect it separately. There is no need to carry out complicated cleaning operations on the entire antibacterial mask, which greatly saves time and energy for cleaning and maintenance. The transparent acrylic material itself has the characteristic of excellent transparency, which allows the wearer to clearly see the external environment through the protective cover 8.

[0117] The protective shield 8 can cover the wearer's entire face, extending from the top of the forehead to the bottom of the chin, and from one cheek to the other. This effectively blocks a wide range of pollutants from the external environment, such as dust, droplets, bacteria, and viruses, from coming into direct contact with the wearer's face, providing comprehensive protection.

[0118] The protective mask 8 is provided with a plurality of breathing holes 801 at the corresponding wearer's mouth and nose. These breathing holes 801 are reasonably designed to fully ensure that the wearer can breathe smoothly when wearing the mask, and ensure that air can flow in and out of the mask freely to meet normal breathing needs.

[0119] The protective cover 8 also includes a shielding portion 802, which is located above the wearer's nose and mouth, and below the eyes. The shielding portion 802 extends toward the protective layer 1. When the drug 7 is discharged from the protective layer 1, it may rise to the eyes and cause irritation. The shielding portion 802 effectively prevents this from happening, further protecting the wearer's eye health.

[0120] The above description is merely a specific embodiment of the present disclosure, but the scope of protection of the present disclosure is not limited thereto. Any changes or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in this disclosure should be included in the scope of protection of the present disclosure. Therefore, the scope of protection of the present disclosure should be based on the scope of protection of the claims.

Claims

1. An antibacterial mask, characterized in that: include: From the outside to the inside, a protective layer, a filter layer and a skin-friendly layer are arranged in sequence; The protective layer is used to block large particles of impurities in the external environment; The filter layer is used to filter one or more harmful substances in the external environment; The skin-friendly layer is used to directly contact with the facial skin of the wearer; A drug releasing device is connected to the protective layer, the drug releasing device has at least one drug releasing end, the drug releasing end passes through the protective layer and is arranged between the protective layer and the filter layer, and the drug releasing device is used to release drugs between the protective layer and the filter layer.

2. The antibacterial mask according to claim 1, characterized in that: The drug release device comprises: A shell, the shell being buckled on the surface of the protective layer and enclosing a containing space with the protective layer; A medicine storage tank, the medicine storage tank is used to store medicine, the medicine storage tank is arranged in the accommodating space and communicated with the medicine release end; A driving unit is connected to the medicine storage tank and is used to drive the medicine in the medicine storage tank to enter the medicine release end.

3. The antibacterial mask according to claim 2, characterized in that: The drug release device further comprises a connecting pipe, wherein the connecting pipe is connected to the drug storage tank and the drug release end respectively; The connecting pipe is a hose.

4. The antibacterial mask according to claim 2, characterized in that: The drug release end is a plate-like structure, and there are multiple drug release ends, and the multiple drug release ends are evenly distributed between the protective layer and the filter layer; There is a distance between the protective layer and the filter layer, and the distance is adapted to the thickness of the drug release end.

5. The antibacterial mask according to claim 2, characterized in that: The drug release device further comprises a detection unit and a control unit, wherein the detection unit is disposed between the protective layer and the filter layer, and the detection unit is used to detect the concentration of viruses or bacteria between the protective layer and the filter layer; The control unit is respectively connected to the detection unit and the driving unit for communication, and the control unit controls the start and stop of the driving unit according to the detection result of the detection unit.

6. The antibacterial mask according to claim 1, characterized in that: The filter layer includes a first antibacterial layer, a second antibacterial layer and a third antibacterial layer which are stacked; The first antibacterial layer is disposed close to the protective layer, and the first antibacterial layer is made of an antibacterial material containing copper ions; The second antibacterial layer is located between the first antibacterial layer and the third antibacterial layer, and the second antibacterial layer is made of a material containing nanosilver; The third antibacterial layer is arranged close to the skin-friendly layer, and the third antibacterial layer is made of a material containing natural plant antibacterial extracts.

7. The antibacterial mask according to claim 1, characterized in that: Also includes: An isolation layer is disposed between the filter layer and the skin-friendly layer, and is used to prevent the drug from contacting the skin-friendly layer.

8. The antibacterial mask according to claim 4, characterized in that: Also includes: A plurality of connecting parts, each of which is in the shape of a rod made of fiber material, and each of which has two ends connected to the protective layer and the filter layer respectively; The plurality of connecting parts are evenly distributed between the protective layer and the filter layer, and the connecting parts are arranged to avoid the range where the drug release end is located.

9. The antibacterial mask according to claim 8, characterized in that: The plurality of connecting parts are located on the surface of the filter layer to form a pair of oppositely arranged accommodating areas, the pair of accommodating areas are respectively arranged corresponding to the cheek sides of the wearer, each of the accommodating areas is used to place one of the drug release ends, and the size of the accommodating areas is adapted to the drug release end; The drug release end is provided with two side surfaces along the thickness direction thereof in contact with the filter layer and the protective layer respectively, and a plurality of through holes are provided along the peripheral side surface of the drug release end perpendicular to the thickness direction, and the drug enters between the plurality of connecting parts through the through holes; The medicine is in any form of mist, granule or liquid.

10. The antibacterial mask according to claim 9, characterized in that: The air permeability of the protective layer is greater than that of the filter layer, the medicine is in granular form, and the medicine can be vaporized under temperature changes.

Images